Overview

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

Status:
Not yet recruiting

Trial end date:
2020-11-01

Target enrollment:
0

Participant gender:
All

Summary

This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hospital Sao Domingos

Treatments:

Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate

Criteria

Inclusion Criteria:

Men and non-pregnant women over 18 years old COVID diagnosis confirmed by real time
polymerase chain reaction (RT-PCR) Pao2 / FIO2 <200 Laboratory: high sensitivity C reactive
protein> 5 mg / L; lactic dehydrogenase (LDH ) > 245 U / l; Ferritin> 300; D-dimer> 1500;
Interleukin-6> 7.0 pg / ml.

Exclusion Criteria:

- Known sensitivity/Allergy to tocilizumab

- Active tuberculosis

- Pregnancy

- Individuals, in the opinion of the investigators where progression to death is
imminent and inevitable in the next 24 hours